Medical Oncologist
Resistance & next-line options
Why Does Targeted Therapy — Stop Working?
Targeted therapy works until cancer cells find a way around it. Understanding why that happens — and what it means for what comes next — is the most useful thing you can know at this point.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Resistance is anticipated — For most targeted therapies, resistance is a predictable biological event, not an unexpected failure. Oncologists plan around it from the start.
- The tumour changes during treatment — The cancer that exists at progression is biologically different from the one treatment started on. Re-testing identifies what has changed.
- The mechanism matters — How resistance developed determines which next-line treatment is most likely to work. Two people on the same drug can progress through different routes.
- Next options depend on re-testing — NCCN and ESMO guidance recommends molecular testing at progression, because matched next-line options exist for some — but not all — resistance patterns.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Targeted therapy stops working when cancer cells develop changes that get around the drug's mechanism of action. This is called acquired resistance. NCCN and ESMO guidance recommends re-testing at the point of progression to identify the resistance mechanism, because the next-line treatment depends on what has changed in the tumour.
Why does targeted therapy stop working over time?
Targeted therapy works by blocking a specific molecular switch that the tumour depends on to grow. Not every cancer cell in the tumour is identical, and the cells that survive the initial treatment are often those with a natural ability to find a workaround.
Those surviving cells divide and eventually take over. When scans show the cancer growing again, the tumour you have now is biologically different from the one treatment started on.
This is called acquired resistance. It is not a sign that something went wrong — it is a predictable biological event that oncologists anticipate and plan for from the start of treatment.
What do the terms your team might use actually mean?
- Acquired resistance
- Resistance that develops after the treatment has initially worked. The tumour was sensitive to the drug, then adapted to get around it.
- Primary resistance
- When the treatment never worked from the start. The tumour had a way around the drug even before it was given.
- On-target resistance
- The cancer cell mutates the same protein the drug was blocking, so the drug can no longer bind to and block it effectively.
- Off-target resistance
- The cancer cell activates a completely different pathway to keep growing, bypassing the one the drug was designed to block.
- Bypass track
- An alternative signalling route the cancer uses to drive growth, even when its usual route has been blocked by the drug.
- Liquid biopsy
- A blood test that detects DNA shed by cancer cells into the bloodstream, used to look for resistance mutations without requiring a tissue biopsy.
What are the most common ways resistance develops?
The most common route is a new mutation in the same gene the drug was targeting. The mutated protein still functions for the cancer cell, but the drug can no longer fit and block it.
A second common route is activation of a different growth pathway. The drug blocks the usual route and the cancer cell finds a side door — a different set of signals that achieve the same end result.
Less commonly, some tumours change their cell type during treatment. A cancer driven by a specific mutation may transform into a form that no longer depends on that mutation, making the original drug irrelevant.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
How does your team find out which type of resistance has developed?
Re-testing at the point of progression is how the resistance mechanism is identified. NCCN and ESMO both recommend this as a standard step before deciding on next-line treatment.
Testing may use a new tissue biopsy from a growing lesion, a liquid biopsy from blood, or both. Which is recommended depends on what is accessible and what your oncologist is looking for.
The result directly shapes what comes next. Two people who progress on the same first-line targeted therapy may have developed different resistance mechanisms and need different second-line treatments.
What are the next-line options after targeted therapy stops working?
A next-generation targeted drug designed for the resistance mutation
For some resistance mechanisms, a newer drug has been developed that works even in the presence of the mutation that caused resistance to the first drug. Whether this applies to you depends on what the re-testing shows and what your oncologist determines is appropriate for your specific situation. Not every resistance mutation has a matched next-generation drug, and new agents in this space are being studied in clinical trials for patterns that do not yet have an approved option.
A targeted therapy aimed at an alternative pathway
When the cancer has activated a bypass track — a different signalling route rather than a mutated version of the original target — the next-line option may be a drug that blocks that alternative pathway instead, sometimes in combination with the original drug. Identifying this pattern requires molecular testing, which is why re-testing at progression is recommended before making a next-line decision. Your oncologist will explain whether your specific resistance pattern has a matched option available.
Chemotherapy
When resistance has developed in a way that does not have a targetable mutation or bypass pathway, chemotherapy is often the recommended next-line treatment. This is a shift in approach rather than a last resort — chemotherapy works through a different mechanism and does not require a specific molecular target, so it can remain effective even after targeted therapy resistance has developed. Your oncologist will explain what regimen applies to your cancer type and what it is intended to achieve.
Immunotherapy
In some cancers and some resistance settings, immunotherapy becomes an option after targeted therapy has stopped working. Whether this applies depends on your tumour's biomarkers — including PD-L1 expression and microsatellite instability — which may be tested at the point of progression. Immunotherapy and targeted therapy are generally not given together outside a clinical trial. Eligibility is based on your specific biomarker results, not on the fact that you have previously had targeted therapy.
A clinical trial of a new agent or combination
For resistance mechanisms that do not yet have an approved matched drug, a clinical trial may be the best available option. Trials are specifically designed for patients who have progressed on targeted therapy, testing agents aimed at known resistance patterns. Your oncologist can look for trials that match your specific mechanism. Enrolment is voluntary, and before any decision you would be told exactly what is being tested, what the alternatives are, and what participation involves.
Did you know?
In some cancers, the molecular change that drives resistance can be detected in a blood sample — a liquid biopsy — before it becomes visible on imaging.
Identifying the resistance mechanism as soon as progression is confirmed is what keeps the widest range of next-line options available.
Source: NCCN Guidelines for Treatment of Cancer by Site; ESMO Clinical Practice Guidelines on Molecular Testing
Explore 39 more Monitoring, Resistance & Long-Term Response topics
Resistance, Progression & Next Lines
- Being Told 'There Are No More Options': Is That Really True?
- Brain Metastases on Targeted Therapy: Does Your Drug Reach the Brain?
- Can You Continue the Same Drug After Progression?
- Combination Therapy to Overcome Resistance
- Do You Need Another Biopsy When the Cancer Progresses?
- Histologic Transformation: When Lung Cancer Changes Type
- How to Emotionally Process a Progression Scan
- Leptomeningeal Disease: Symptoms, Diagnosis and Treatment
- Life After ALK Inhibitor Resistance: Sequencing Your Options
- MET Amplification and Other Bypass Resistance Mechanisms
- Oligoprogression: When Only One or Two Spots Grow
- Primary vs Acquired Resistance: Two Very Different Problems
- Should You Change Hospitals After Progression?
- What Happens After Osimertinib Stops Working?
- What Is Sequencing and Why the Order of Drugs Matters
- Why Does Targeted Therapy Stop Working? The Biology of Resistance
Long-Term Response, Stopping & Survivorship
- Am I Still a Cancer Patient? Identity After Long-Term Response
- Bone Health, Heart Health and Late Effects to Monitor
- Can You Ever Stop Targeted Therapy If the Cancer Is Gone?
- Drug Holidays: Are Planned Breaks Safe?
- Follow-Up Schedule After Stopping Targeted Therapy
- How Long Do You Have to Stay on Targeted Therapy?
- Long-Term Effects of Taking a TKI for 5 or 10 Years
- Restarting Treatment After a Break
- Treatment-Free Remission in CML: Who Can Stop Their TKI?
- Your Survivorship Care Plan: What Should Be In It
Monitoring, Scans & Response Assessment
- Are Tumour Markers Reliable on Targeted Therapy?
- Complete Response, Partial Response, Stable Disease: What Each Means
- Do I Need Regular Brain MRIs on Targeted Therapy?
- How Doctors Measure Whether Targeted Therapy Is Working
- How Often Will I Need Scans on Targeted Therapy?
- How to Read a CT or PET Scan Report Without Panicking
- Is 'Stable Disease' Good News or Bad News?
- Scanxiety: How to Get Through the Wait for Scan Results
- Tumour Flare and Pseudoprogression: When Growth Isn't Really Growth
- Understanding PFS, OS and Median Survival Without Losing Hope
- What Happens at a Follow-Up Visit: A Walk-Through
- Which Blood Tests Are Repeated Every Month and Why
- ctDNA Monitoring: Can a Blood Test Predict Progression Early?
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Does resistance mean the treatment has failed?
No — resistance means the treatment worked until the cancer adapted. The drug did what it was designed to do. Most targeted therapies are expected to develop resistance eventually, and oncologists factor this into the treatment plan from the beginning. Resistance is the signal to move to the next step, not the end of options.
How long does targeted therapy usually work before resistance develops?
There is no single answer that applies to all targeted therapies or all patients, and a figure quoted without your specific situation in mind is not reliable guidance. Response duration varies by cancer type, the specific mutation being targeted, and individual factors. NCCN and ESMO guidance focuses on monitoring for progression rather than predicting a timeline. Your oncologist can give you a realistic expectation based on the evidence for your specific cancer and mutation.
Can I go back to the first targeted therapy if the next-line treatment also stops working?
In a small number of situations, yes — and whether it is worth considering depends on what resistance mechanism developed during second-line treatment. If the cancer has lost the resistance mutation that made it insensitive to the first drug, there may be a rationale. This is not a standard approach and would be based on re-testing at that later point of progression. Your oncologist would assess it if the question becomes relevant rather than planning for it now.
Is there any way to prevent resistance from developing?
Not in any established, predictable way. Researchers are studying whether combining targeted drugs from the start delays resistance by blocking multiple pathways simultaneously, and some combination approaches are already part of standard care for specific cancers. For most targeted therapies given as single agents, resistance is anticipated eventually. The practical focus is on monitoring closely enough to detect it early, then moving quickly to a next-line option matched to the specific mechanism identified.
Do I need a new biopsy when the cancer progresses on targeted therapy?
NCCN and ESMO guidance recommends re-testing at progression in most targeted therapy settings, because the resistance mechanism shapes which next-line treatment is most appropriate. Whether that means a tissue biopsy, a liquid biopsy from blood, or both depends on which lesion is most accessible and what your oncologist is looking for. If a new biopsy is recommended, it is reasonable to ask what the test is expected to show and how the result will change the next-line plan.
What should I ask my oncologist after being told the cancer has progressed?
Ask four things: what the scans show specifically and in which sites, whether molecular re-testing is being recommended and what it is looking for, what the next-line options are and what each is intended to achieve, and whether a clinical trial is appropriate for your resistance pattern. At CION, resistance assessment and next-line planning are part of the same conversation — chemotherapy and immunotherapy are administered as day care, and any response-assessment imaging is coordinated through partner centres.